AbbVie reported better skin and itch results in an eczema study and weight loss in an early drug study. These findings add promise to its drug work, though neither study shows a treatment is ready for patients.
This gives AbbVie more possible treatments across 2 disease areas. The results are encouraging, but these early studies do not show whether either drug will be approved or become a successful treatment.
Follow AbbVie Inc. (ABBV) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ABBV